The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  66 (2024)
Volume  65 (2023)
Volume  64 (2022)
Volume  63 (2021)
Volume  62 (2020)
Volume  61 (2019)
Volume  60 (2018)
Volume  59 (2017)
Volume  58 (2016)
Volume  57 (2015)
Volume  56 (2014)
Volume  55 (2013)
Volume  54 (2012)
Volume  53 (2011)
Volume  52 (2010)
Related articles

VOLUME 59 , ISSUE 2 ( April-June, 2017 ) > List of Articles

EDITORIAL

Is There Any Hope for Preventing Replacement of All Drug Sensitive Tuberculosis Cases by Drug Resistant Tuberculosis?

Rajendra Prasad, Amitabh Banka, Nikhil Gupta

Citation Information : Prasad R, Banka A, Gupta N. Is There Any Hope for Preventing Replacement of All Drug Sensitive Tuberculosis Cases by Drug Resistant Tuberculosis?. Indian J Chest Dis Allied Sci 2017; 59 (2):65-67.

DOI: 10.5005/ijcdas-59-2-65

License: CC BY-NC 4.0

Published Online: 18-06-2017

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract
PDF Share
  1. World Health Organization. Global Tuberculosis Report 2016. WHO/HTM/2016.13. Geneva: World Health Organization; 2016.
  2. Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE, Chadha VK, et al. The tuberculosis cascade of care in India's public sector: a systematic review and meta-analysis. PLoS Med 2016;13:e1002149. doi:10.1371/journal.pmed.1002149.
  3. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrugresistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017;5:291-360.
  4. Jain A, Dixit P, Prasad R. Pre XDR and XDR in MDR and ofloxacin and kanamycin resistance in non MDR mycobacterium tuberculosis isolates. Tuberculosis 2012;92:404-6.
  5. Udwadia Z, Jain S, Rodrigues C, Mehta A. XDR-TB in India: what's in a name? The Lancet Infect Dis 2007;7:441-2.
  6. Mondal R, Jain A. Extensively drug-resistant Mycobacterium tuberculosis, India, India (letter). Emerg Infect Dis 2007;13:1429-31.
  7. Thomas A, Ramachandran R, Rehman F, Jaggarajamma K, Santha T, Selvakumar N, et al. Management of multi drug resistant tuberculosis in the field: Tuberculosis Research Centre. Indian J Tub 2007;54:117-24.
  8. Prasad R, Gupta N, Banka A. 2025 too short time to eliminate tuberculosis from India. Lung India 2017;34:409-10.
  9. Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 2015;373:1986-8.
  10. Sharma A, Hill A, Kurbatova E, Walt MVD, Kvasnovsky C, Tupasi TE, et al. Estimating the future burden of multidrugresistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. The Lancet Infect Dis 2017;17;707-15.
  11. Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med 2015;3:963-72.
  12. Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med 2017;376:243-53.
  13. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 2016;48:16-25.
  14. Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KR. GenoTypeMTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2016;9:CD010705.
  15. World Health Organization. WHO Treatment Guidelines for Drug-resistant Tuberculosis 2016 Update. WHO/HTM/TB/2016.04. Geneva: World Health Organization; 2016.
  16. Kendall EA, Fojo AT, Dowdy DW. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respir Med 2017;5:191-9.
  17. Conradie F, Diacon A, Everitt D, Mendel C, van Niekerk C, Howell P, et al. The Nix-TB trial of pretomanid, bedaquiline, and linezolid to treat XDR-TB. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; Feb 13-16, 2017.
  18. World Health Organization. Target Regimen Profiles for TB Treatment. WHO/HTM/TB/2016.16. Geneva: World Health Organization; 2016.
  19. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6.
  20. Hollo C. National Tuberculosis Registry, Estonia. Tendencies of tuberculosis incidence in Estonia, 1998-2006. Available at URL: http://www.epinorth.org/eway/default.aspx?pid=230&trg=Area_5268&MainArea_5260=5263:0:15, 2946:1:0:0:::0:0&Area_5263=5268:44984::1:5264:1:::0:0&Area_5268=5273:45867::1:5266:3:::0:0. Accessed on September 11, 2017.
  21. Friedland G. Significant and sustained decline in extensively and multiple drug resistant tuberculosis (XDR/MDR TB) from 2005-2014 in Tugela Ferry, KwaZulu-Natal, South Africa. TB2016; Durban, South Africa; July 16-17, 2016.
  22. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014;18:1188-94.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.